Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Italy
Italy- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
113 trials match your criteria
Recruiting
Primary progressive multiple sclerosis
RecruitingInvestigational
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis
Investigational
- Disease:Primary progressive multiple sclerosis
- Substances:–
Countries:Italy
Italy- Participants:18–64 years
Recruiting
Agitation+1
RecruitingInvestigational
A study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer's disease
Investigational
- Disease:AgitationDementia Alzheimer's type
- Substances:Dextromethorphan Hydrobromide
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Dextromethorphan Hydrobromide
Recruiting
Cardiac failure+1
RecruitingInvestigational
Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity
Investigational
- Disease:Cardiac failureObesity
- Substances:–
Countries:Italy
Italy- Participants:18–64 years · 65+ years
Recruiting
Psoriasis
RecruitingRegistered drugNo placebo
Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis
Registered drugNo placebo
- Disease:Psoriasis
- Substances:DeucravacitinibUstekinumab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Deucravacitinib
Recruiting
Generalised tonic-clonic seizure+1
RecruitingInvestigationalNo placebo
Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures
InvestigationalNo placebo
- Disease:Generalised tonic-clonic seizurePartial seizures
- Substances:Prax-628VORMATRIGINE
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Prax-628
Recruiting
Cardiovascular disorder+2
RecruitingRegistered drug
Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease
Registered drug
- Disease:Cardiovascular disorderType 2 diabetes mellitus+1
- Substances:Bi 690517Empagliflozin
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Bi 690517
Recruiting
Arteriosclerosis
RecruitingInvestigational
Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease
Investigational
- Disease:Arteriosclerosis
- Substances:Maridebart Cafraglutide
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Maridebart Cafraglutide
Recruiting
Major depression
RecruitingInvestigational
Study on Seltorexant for Adults and Elderly with Major Depressive Disorder and Insomnia Symptoms
Investigational
- Disease:Major depression
- Substances:SELTOREXANT
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:SELTOREXANT
Recruiting
Partial seizures
RecruitingInvestigationalNo placebo
Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy
InvestigationalNo placebo
- Disease:Partial seizures
- Substances:Bhv-7000
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Bhv-7000
Recruiting
Obesity+1
RecruitingInvestigational
A Phase 3 Study of Once‑Monthly PF‑08653944 vs Placebo for Weight Loss in Adults with Overweight or Obesity
Investigational
- Disease:ObesityOverweight
- Substances:–
Countries:Italy
Italy- Participants:18–64 years · 65+ years
Recruiting
Depression
RecruitingRegistered drugNo placebo
Safety and dose‑finding study of trazodone hydrochloride and psilocybin in patients with treatment‑resistant depression
Registered drugNo placebo
- Disease:Depression
- Substances:Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: MethanolTRAZODONE HYDROCHLORIDE
Countries:Italy
Italy- Participants:18–64 years
- Substances:Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol